Indication

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

• About Ventavis

• About the I-neb AAD
  System

• Services for Your Patients

•      Specialty Pharmacy

• Resources

• Prescribing Information

• For Patients and
  Caregivers

PAH Pathways™

Your patients are automatically enrolled in the PAH Pathways program when you prescribe Ventavis^® (iloprost) Inhalation Solution. They are contacted by our Pathways counselors and our specialty pharmacy nurses in order to handle reimbursement and Ventavis dosage and administration training.

For more information on how PAH Pathways works for your patients, make an appointment with one of our representatives.

• Insurance help: Your patient's PAH Pathways counselor will verify insurance coverage and clarify the co-payment amount before the prescription is filled.
• Financial Assistance: Actelion sponsors some financial assistance programs for eligible patients; others are available through alternative sources. PAH Pathways can help your patients find and apply for the appropriate program or programs available to them.
• Access to therapy: Once benefits are verified, we will arrange for delivery of the medication directly to your patient's home.

IMPORTANT SAFETY INFORMATION

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHG. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause brochospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information